SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies

Launched by ·

Keywords

ClinConnect Summary

This clinical trial is testing a new treatment called supCD7 CART cells for people with certain types of blood cancers that have come back or did not respond to previous treatments. These cancers include T lymphoblastic leukemia/lymphoma and acute myeloid leukemia (AML), which affect the blood and bone marrow. The goal of the study is to find out if this treatment is safe and how well it works in these patients.

The trial is currently looking for adults who have these specific types of blood cancers that are positive for a marker called CD7 and have not improved with other treatments. Participants will receive the supCD7 CART cells through an intravenous (IV) infusion. The study will carefully increase the dose to find the best and safest amount to give. Since this is an early-phase trial, patients will be closely monitored for side effects and treatment response. This trial is open to both men and women, and it takes place at a single medical center.

Gender

ALL

Eligibility criteria